Tolebrutinib did not cut MS relapses more than Aubagio
Key Takeaway
In two trials of relapsing MS, tolebrutinib did not reduce flare-ups more than Aubagio.
What They Found
In the first trial, both groups had about the same number of flare-ups each year. The second trial also found about the same number of flare-ups in both groups. Across both trials, disability worsened for about 8% taking tolebrutinib and about 11% taking teriflunomide (Aubagio). Overall, similar shares of both groups reported side effects. Small spots of bleeding under the skin and heavy periods were more common with tolebrutinib.
Who Should Care and Why
The trials studied people with relapsing MS. Researchers compared tolebrutinib with teriflunomide (Aubagio). Both medicines were taken by mouth each day. The main question was whether tolebrutinib reduced flare-ups more than Aubagio. The trials also tracked lasting disability worsening and side effects.
Important Considerations
You should know these were two trials with 1,873 participants in total, assigned to treatments by chance. The disability results were not formally tested, so they do not establish that tolebrutinib prevents more worsening. You should also know that the middle length of follow-up was 139 weeks.
AI-generated summary — for informational purposes only, not medical advice
Categories:
You May Also Like
11/1/2026
Researchers compared blood from people with childhood-onset MS and healthy volunteers. They found DN
Read More
11/1/2026
In 24 people with severe MS, stem cell treatment lowered signs of inflammation and nerve damage for
Read More
11/1/2026
A review of 49 studies finds special brain scans can detect MS-related inflammation, but scan method
Read More
11/1/2026
In a study of 294 pregnancies, MS flare-ups were uncommon after pausing two treatments. Learn what t
Read More
10/9/2026
A mouse study suggests prepared red blood cells may calm MS-like immune attacks. Learn why liver cel
Read More
10/9/2026
See how lab-grown nerve cells move a key protein, why this may matter for nerve health, and why the
Read MoreUnderstanding MS Research
Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like The New England journal of medicine often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.
However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.
By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.